Shares of Eli Lilly & Co. and Novo Nordisk A/S fell after US regulators established a “green list” of foreign manufacturers who produce raw materials that compounding pharmacies use to make copies of their blockbuster GLP-1 drugs.
Shares of Eli Lilly & Co. and Novo Nordisk A/S fell after US regulators established a “green list” of foreign manufacturers who produce raw materials that compounding pharmacies use to make copies of their blockbuster GLP-1 drugs. by Soban News (international And National News)
